BIOCHEMISTRY, BIOMEDICINE & PHARMACEUTICS

TOPAMAX (topiramate), FDA Approved Drug For the Treatment of Epilepsy Topiramate is a sulfamate-substituted monosaccharide. TOPAMAX (topiramate). Topiramate is designated chemically as 2,3:4,5­ Di-O-isopropylidene-beta-D-fructopyranose sulfamate. TOPAMAX (topiramate capsules) Sprinkle Capsules are available as 15 mg and 25 mg sprinkle capsules for oral administration as whole capsules or opened and sprinkled onto soft food. Indication of TOPAMAX TOPAMAX (topiramate) is indicated for:  Monotherapy epilepsy: Initial monotherapy in patients with & above 2 years of age with partial-onset or primary generalized tonic-clonic seizures    Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial-onset seizures or primary generalized tonic-clonic seizures, and in patients with and above 2 years of age with seizures associated with Lennox-Gastaut syndrome (LGS) ( Migraine: Treatment for adults and adolescen...

    About Autolus Therapeutics plc Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.  Pipeline AUTO1 / AUTO1-AL1 – Adult Acute Lymphoblastic Leukemia (ALL) and Pediatric ALL AUTO1 is a CD19 CAR T cell investigational therapy designed to overcome the limitations in safety - while maintaining similar levels of efficacy - compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, AU...